CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 120 enrolled
Drug / intervention
Berberine Hydrochloride group +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06703086
NCT06703086N/ACompleted

Gene Modulation of NLRP3, IL-1β and TNF-α in Peripheral Blood of Patients With Exogenous Obesity Treated With Berberine

National Polytechnic Institute, Mexico·interventional·Posted Nov 25, 2024·Updated Nov 25, 2024

In Brief

A clinical study evaluating Berberine Hydrochloride group, nutritional plan, and 1 other intervention for Obesity and 2 related conditions. Completed, enrolled 120 participants.

Detailed Summary

The patients will be invited to participate in a research study aimed at determining the Gene Modulation of NLRP3, IL-1β and TNFα in peripheral blood of patients with exogenous obesity treated with berberine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedNov 25, 2024
Enrollment StartJan 5, 2019
Primary CompletionAug 15, 2019
Study CompletionFeb 15, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 1.6 years ago

Interventions

Berberine Hydrochloride groupdietary

The patient will be given a nutritional plan, moderate aerobic exercise with a goal of 10,000 steps or 150 min per week; and the phytopharmaceutical Berberine will be taken 3 tablets ( 500 mg) every 8 hours for 3 months.

nutritional planbehavioral

nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months

controlled moderate aerobic exercisebehavioral

controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week.